School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiang'an South Road, Xiamen, Fujian 361102, China.
Howard Hughes Medical Institute, Department of Medicine, School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Mol Cell. 2018 Apr 19;70(2):340-357.e8. doi: 10.1016/j.molcel.2018.03.006. Epub 2018 Apr 5.
Whereas the actions of enhancers in gene transcriptional regulation are well established, roles of JmjC-domain-containing proteins in mediating enhancer activation remain poorly understood. Here, we report that recruitment of the JmjC-domain-containing protein 6 (JMJD6) to estrogen receptor alpha (ERα)-bound active enhancers is required for RNA polymerase II recruitment and enhancer RNA production on enhancers, resulting in transcriptional pause release of cognate estrogen target genes. JMJD6 is found to interact with MED12 in the mediator complex to regulate its recruitment. Unexpectedly, JMJD6 is necessary for MED12 to interact with CARM1, which methylates MED12 at multiple arginine sites and regulates its chromatin binding. Consistent with its role in transcriptional activation, JMJD6 is required for estrogen/ERα-induced breast cancer cell growth and tumorigenesis. Our data have uncovered a critical regulator of estrogen/ERα-induced enhancer coding gene activation and breast cancer cell potency, providing a potential therapeutic target of ER-positive breast cancers.
虽然增强子在基因转录调控中的作用已得到充分证实,但 JmjC 结构域蛋白在介导增强子激活中的作用仍知之甚少。在这里,我们报告说,JmjC 结构域蛋白 6(JMJD6)被招募到雌激素受体 alpha(ERα)结合的活性增强子上,是招募 RNA 聚合酶 II 和增强子 RNA 产生所必需的,从而导致同源雌激素靶基因的转录暂停释放。发现 JMJD6 与中介复合物中的 MED12 相互作用,以调节其募集。出乎意料的是,JMJD6 对于 MED12 与 CARM1 的相互作用是必需的,CARM1 在多个精氨酸位点甲基化 MED12,并调节其染色质结合。与它在转录激活中的作用一致,JMJD6 是雌激素/ERα 诱导的乳腺癌细胞生长和肿瘤发生所必需的。我们的数据揭示了雌激素/ERα 诱导的增强子编码基因激活和乳腺癌细胞效力的关键调节因子,为 ER 阳性乳腺癌提供了一个潜在的治疗靶点。